Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00011068
DRKS00011068
Completed
Not Applicable

Pharmacy based non-interventional study (NIS) assessing the efficacy and safety of Esberitox® COMPACT in case of colds - SB-TOX 0116

Schaper & Brümmer GmbH & Co. KG0 sites960 target enrollmentSeptember 21, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsViral cold diseasesJ06.9Acute upper respiratory infection, unspecified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Viral cold diseases
Sponsor
Schaper & Brümmer GmbH & Co. KG
Enrollment
960
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 21, 2016
End Date
May 17, 2017
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients who intend to treat their acute cold with Esberitox® COMPACT in line with the package information leaflet and who are invited by the pharmacist / the qualified staff to participate in the study.
  • •\- Written data collection consent has been obtained.

Exclusion Criteria

  • •Contraindications of Esberitox® COMPACT according to the package information leaflet.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
Clinical study of Darvyadi Granules in Iron Deficiency Anaemia.Health Condition 1: D508- Other iron deficiency anemiasHealth Condition 2: D508- Other iron deficiency anemias
CTRI/2020/04/024459Parul University
Completed
Not Applicable
A multi-center non-interventional study (NIS) to assess practicability, effectiveness and tolerability of once daily applied tacrolimus formulations used in kidney transplant patients.Immunosuppression after kidney transplantationZ94Transplanted organ and tissue status
DRKS00011124Chiesi GmbH47
Active, not recruiting
Not Applicable
An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutideDiabetesMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2011-001935-21-ITIPSEN PHARMA SAS29
Recruiting
Not Applicable
This study is being conducted to evaluate the safety and efficacy of a strategy of early fibrinolytic treatment with Reteplase (rPA) in patients with ST- segment elevation myocardial infarction (STEMI).Health Condition 1: null- STEMI
CTRI/2017/09/009796STEMI INDIA200
Recruiting
Not Applicable
Outcome Measure of Pharmacist-led Intervention for Chronic Kidney Disease PatientsChronic kidney disease
JPRN-UMIN000049914Kinjo Gakuin University50